Shalini Prasad
Appearances
- DateMay 7, 2023Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Presenter
- DateMay 19, 2024Wearable sensors present an opportunity to monitor inflammation via noninvasive mediums such as perspiration, which can be sampled continuously to track inflammation-related markers in inflammatory bowel disease (IBD)…
- DateMay 19, 2024Background: Inflammatory bowel disease (IBD) monitoring currently relies on patient reported symptoms or cross-sectional assessments of blood, stool, imaging or endoscopy. Advances in wearable technology provide a novel means to monitor IBD activity in real time, remotely and passively…